Philippines at a glance
- Population
- 116.8 million 2025
- Life expectancy at birth
- 69.9 years, 2024
- People aged 65 and over
- 5.7 % of people, 2025
- Health spending per person
- 194 US$ per person, 2023
- Doctors
- 0.79 per 1,000 people, 2021
Updated
Reviewed by Chandani Patel
Philippines Liver Cirrhosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Cause, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$18.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $27.5 Mn | — | — |
| 2025 (base) | $29.0 Mn | +$1.5 Mn | — |
| 2026 (forecast) | $30.6 Mn | +$1.6 Mn | +5.6% |
| 2027 (forecast) | $32.3 Mn | +$1.7 Mn | +11.5% |
| 2028 (forecast) | $34.1 Mn | +$1.8 Mn | +17.8% |
| 2029 (forecast) | $36.1 Mn | +$1.9 Mn | +24.4% |
| 2030 (forecast) | $38.1 Mn | +$2.0 Mn | +31.3% |
| 2031 (forecast) | $40.2 Mn | +$2.1 Mn | +38.7% |
| 2032 (forecast) | $42.5 Mn | +$2.3 Mn | +46.4% |
| 2033 (forecast) | $44.8 Mn | +$2.4 Mn | +54.6% |
| 2034 (forecast) | $47.3 Mn | +$2.5 Mn | +63.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $29.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $47.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, cause and end user (see all) |
| Key players | Salix (Bausch Health), Gilead Sciences, Inc., Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Novo Nordisk A/S (see all) |
| Regulator in the Philippines | FDA PhilippinesSource: Food and Drug Administration Philippines. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Liver cirrhosis treatments manage scarring of the liver and its complications such as fluid build-up and confusion.
Key segments of the liver Cirrhosis Treatment market include treatment (Medications, Liver Transplant and Nutrition Support) and cause (Alcohol-Related, MASH-Related and Viral Hepatitis).
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the liver Cirrhosis Treatment market.
Microbiome-based treatments, earlier testing and digital gut-health programmes give the liver Cirrhosis Treatment market room to grow.
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the liver Cirrhosis Treatment market.
The liver Cirrhosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Drug products need registration with the Food and Drug Administration of the Philippines (FDA).[1] PhilHealth is the national health insurer, and the Universal Health Care Act of 2019 makes every Filipino a member.[2]
[1] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[2] PhilHealth. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for liver Cirrhosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in the Philippines.
What doctors and scientists are doing in Liver Cirrhosis Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
Philippines
Philippines
Philippines
Philippines
Philippines
Philippines
OTC & Nutraceuticals · Philippines
Public Health · Philippines
OTC & Nutraceuticals · Philippines
Healthcare Services · Philippines
Public Health · Global
Public Health · Global